Parag Shah
Plus aucun poste en cours
Fortune : 1 359 $ au 30/04/2024
Profil
Parag Suresh Shah worked as a Director of Pharmaceutical Science at Ikaria, Inc. and later as a Vice President of Business Operations at Bellerophon Therapeutics, Inc. He received an undergraduate degree from Carnegie Mellon University and a doctorate degree from The University of Texas at Austin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/10/2023 | 24 705 ( 0,20% ) | 1 359 $ | 30/04/2024 |
Anciens postes connus de Parag Shah
| Sociétés | Poste | Fin |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Directeur des opérations | 31/08/2023 |
| IKARIA, INC. | Corporate Officer/Principal | - |
Formation de Parag Shah
| Carnegie Mellon University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |